
LINK . SPRINGER . COM {
}
Title:
Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer | World Journal of Urology
Description:
There is no proven, effective, standard second-line chemotherapy for castration- and docetaxel-resistant prostate cancer (DRPC). Recent data suggest that carboplatin may be effective in combination with docetaxel in this setting; however, the optimal docetaxel/carboplatin-based regimen is still unclear. We identified 43 consecutive patients with DRPC treated with carboplatin (AUC5 d1) and docetaxel (35 mg/m2 d1, 8, 15 q4w i.v.) as a second-line or subsequent salvage chemotherapy until discontinuation of therapy due to disease progression or unacceptable toxicity. Decreased prostate-specific antigen (â„50% PSA) was observed in 22/43 (51.2%, 95% CI, 35.5, 66.7%) patients, with â„90% reduction in 12/43 patients (27.9%). At the time of analysis, the median follow-up time for all patients was 10.4 months. Median progression-free survival (PFS) for all patients was 6.5 months (95% CI 4.1, 8.9), and median overall survival (OS) was 15.8 months (95% CI 12.1, 18.5). In PSA responders, PFS was 9.5 (95% CI 8.2, 19.0) months versus 3.3 (95% CI 2.6, 4.0) months in PSA non-responders (P < 0.0001; hazard ratio (HR) 0.108) and OS was 24.4 months (95% CI 19.5, 29.4) versus 7.8 (95% CI 5.2, 10.3) months (P = 0.001; HR 0.232). Established prognostic factors were associated with survival. This regimen was reasonably well tolerated, with leukopenia/neutropenia as the most common reversible grade 3/4 toxicity (41.9/39.5%). These data suggest that weekly docetaxel plus carboplatin may be an important therapeutic second-line treatment option for patients with DRPC.
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {đ}
- Education
- Health & Fitness
- Science
Content Management System {đ}
What CMS is link.springer.com built with?
Custom-built
No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.
Traffic Estimate {đ}
What is the average monthly size of link.springer.com audience?
đ Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {đž}
We can't see how the site brings in money.
The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.
Keywords {đ}
cancer, prostate, article, google, scholar, pubmed, cas, patients, chemotherapy, oncol, docetaxel, study, castrationresistant, secondline, phase, hormonerefractory, carboplatin, clin, docetaxelresistant, therapy, months, clinical, treatment, metastatic, trials, privacy, cookies, content, data, journal, weekly, survival, access, analysis, publish, search, salvage, reuter, combination, toxicity, trial, ann, drugs, author, information, log, research, world, urology, christoph,
Topics {âïž}
castration-resistant prostate cancer docetaxel-resistant prostate cancer arnold ganser & viktor grĂŒnwald hormone-refractory prostate cancer optimal docetaxel/carboplatin-based regimen month download article/chapter androgen-independent prostate carcinoma docetaxel/carboplatin-based chemotherapy initial docetaxel-based chemotherapy prevent docetaxel-induced onycholysis 2nd/3rd line therapy martin fenner docetaxel-based therapy advanced prostate cancer progressive prostate cancer subsequent salvage chemotherapy carboplatin combination chemotherapy article world journal full article pdf related subjects prospective clinical trials recurrent prostate cancers author information authors privacy choices/manage cookies median progression-free survival salvage chemotherapy docetaxel-resistant important therapeutic drug exposure stem cell transplantation carboplatin-taxane combinations check access instant access european economic area established prognostic factors pegylated liposomal doxorubicin biweekly doxorubicin/ketoconazole regan mm testicular steroid biosynthesis carl-neuberg-str author correspondence clinical trials docetaxel-pretreated patients conditions privacy policy cytotoxic agent combinations 35 mg/m2 d1 prospective study evaluating journal finder publish phase ii trial accepting optional cookies
Questions {â}
- Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K (2006) First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
- Oh WK, Tay MH, Huang J (2007) Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
- Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why?
- Schertl S, Hartmann RW, Batzl-Hartmann C et al (2007) Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers?
Schema {đșïž}
WebPage:
mainEntity:
headline:Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer
description:There is no proven, effective, standard second-line chemotherapy for castration- and docetaxel-resistant prostate cancer (DRPC). Recent data suggest that carboplatin may be effective in combination with docetaxel in this setting; however, the optimal docetaxel/carboplatin-based regimen is still unclear. We identified 43 consecutive patients with DRPC treated with carboplatin (AUC5 d1) and docetaxel (35 mg/m2 d1, 8, 15 q4w i.v.) as a second-line or subsequent salvage chemotherapy until discontinuation of therapy due to disease progression or unacceptable toxicity. Decreased prostate-specific antigen (â„50% PSA) was observed in 22/43 (51.2%, 95% CI, 35.5, 66.7%) patients, with â„90% reduction in 12/43 patients (27.9%). At the time of analysis, the median follow-up time for all patients was 10.4 months. Median progression-free survival (PFS) for all patients was 6.5 months (95% CI 4.1, 8.9), and median overall survival (OS) was 15.8 months (95% CI 12.1, 18.5). In PSA responders, PFS was 9.5 (95% CI 8.2, 19.0) months versus 3.3 (95% CI 2.6, 4.0) months in PSA non-responders (P < 0.0001; hazard ratio (HR) 0.108) and OS was 24.4 months (95% CI 19.5, 29.4) versus 7.8 (95% CI 5.2, 10.3) months (P = 0.001; HR 0.232). Established prognostic factors were associated with survival. This regimen was reasonably well tolerated, with leukopenia/neutropenia as the most common reversible grade 3/4 toxicity (41.9/39.5%). These data suggest that weekly docetaxel plus carboplatin may be an important therapeutic second-line treatment option for patients with DRPC.
datePublished:2010-03-14T00:00:00Z
dateModified:2010-03-14T00:00:00Z
pageStart:391
pageEnd:398
sameAs:https://doi.org/10.1007/s00345-010-0527-5
keywords:
Docetaxel
Carboplatin
Salvage chemotherapy
Docetaxel-resistant
Castration-resistant
Prostate cancer
Urology
Nephrology
Oncology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00345-010-0527-5/MediaObjects/345_2010_527_Fig1_HTML.gif
isPartOf:
name:World Journal of Urology
issn:
1433-8726
0724-4983
volumeNumber:28
type:
Periodical
PublicationVolume
publisher:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Christoph W. M. Reuter
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Michael A. Morgan
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
type:Person
name:Philipp Ivanyi
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
type:Person
name:Martin Fenner
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
type:Person
name:Arnold Ganser
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
type:Person
name:Viktor GrĂŒnwald
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer
description:There is no proven, effective, standard second-line chemotherapy for castration- and docetaxel-resistant prostate cancer (DRPC). Recent data suggest that carboplatin may be effective in combination with docetaxel in this setting; however, the optimal docetaxel/carboplatin-based regimen is still unclear. We identified 43 consecutive patients with DRPC treated with carboplatin (AUC5 d1) and docetaxel (35 mg/m2 d1, 8, 15 q4w i.v.) as a second-line or subsequent salvage chemotherapy until discontinuation of therapy due to disease progression or unacceptable toxicity. Decreased prostate-specific antigen (â„50% PSA) was observed in 22/43 (51.2%, 95% CI, 35.5, 66.7%) patients, with â„90% reduction in 12/43 patients (27.9%). At the time of analysis, the median follow-up time for all patients was 10.4 months. Median progression-free survival (PFS) for all patients was 6.5 months (95% CI 4.1, 8.9), and median overall survival (OS) was 15.8 months (95% CI 12.1, 18.5). In PSA responders, PFS was 9.5 (95% CI 8.2, 19.0) months versus 3.3 (95% CI 2.6, 4.0) months in PSA non-responders (P < 0.0001; hazard ratio (HR) 0.108) and OS was 24.4 months (95% CI 19.5, 29.4) versus 7.8 (95% CI 5.2, 10.3) months (P = 0.001; HR 0.232). Established prognostic factors were associated with survival. This regimen was reasonably well tolerated, with leukopenia/neutropenia as the most common reversible grade 3/4 toxicity (41.9/39.5%). These data suggest that weekly docetaxel plus carboplatin may be an important therapeutic second-line treatment option for patients with DRPC.
datePublished:2010-03-14T00:00:00Z
dateModified:2010-03-14T00:00:00Z
pageStart:391
pageEnd:398
sameAs:https://doi.org/10.1007/s00345-010-0527-5
keywords:
Docetaxel
Carboplatin
Salvage chemotherapy
Docetaxel-resistant
Castration-resistant
Prostate cancer
Urology
Nephrology
Oncology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00345-010-0527-5/MediaObjects/345_2010_527_Fig1_HTML.gif
isPartOf:
name:World Journal of Urology
issn:
1433-8726
0724-4983
volumeNumber:28
type:
Periodical
PublicationVolume
publisher:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Christoph W. M. Reuter
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Michael A. Morgan
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
type:Person
name:Philipp Ivanyi
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
type:Person
name:Martin Fenner
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
type:Person
name:Arnold Ganser
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
type:Person
name:Viktor GrĂŒnwald
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:World Journal of Urology
issn:
1433-8726
0724-4983
volumeNumber:28
Organization:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Christoph W. M. Reuter
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
email:[email protected]
name:Michael A. Morgan
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
name:Philipp Ivanyi
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
name:Martin Fenner
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
name:Arnold Ganser
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
name:Viktor GrĂŒnwald
affiliation:
name:Hannover Medical School
address:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
type:PostalAddress
type:Organization
PostalAddress:
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
name:Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {đ}(108)
- https://www.springernature.com/gp/authors's revenue stream
- What is the monthly revenue of https://link.springernature.com/home/?
- How much revenue does https://order.springer.com/public/cart generate?
- What is the earnings of https://submission.springernature.com/new-submission/345/3?
- How much does https://www.springernature.com/gp/librarians/licensing/agc/journals generate monthly?
- What is the monthly revenue of https://doi.org/10.1002/14651858.CD005247.pub2?
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=Second-line%20chemotherapy%20for%20advanced%20hormone-refractory%20prostate%20cancer&journal=Clin%20Adv%20Hematol%20Oncol.&volume=6&issue=118%E2%80%9322&pages=127-132&publication_year=2008&author=Garmey%2CEG&author=Sartor%2CO&author=Halabi%2CS&author=Vogelzang%2CNJ each month?
- How much cash flow does https://doi.org/10.1002%2Fcncr.21695 have monthly?
- Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16456811's earnings
- http://scholar.google.com/scholar_lookup?&title=First-%20and%20second-line%20chemotherapy%20with%20docetaxel%20or%20mitoxantrone%20in%20patients%20with%20hormone-refractory%20prostate%20cancer%3A%20does%20sequence%20matter%3F&journal=Cancer&doi=10.1002%2Fcncr.21695&volume=106&pages=1041-1046&publication_year=2006&author=Michels%2CJ&author=Montemurro%2CT&author=Murray%2CN&author=Kollmannsberger%2CC&author=Nguyen%20Chi%2CK's total income per month
- How much does https://doi.org/10.1016%2Fj.urology.2008.02.048 earn?
- Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18400264
- http://scholar.google.com/scholar_lookup?&title=Biweekly%20doxorubicin%2Fketoconazole%20as%20second-line%20treatment%20in%20docetaxel-resistant%2C%20hormone-refractory%20prostate%20cancer&journal=Urology&doi=10.1016%2Fj.urology.2008.02.048&volume=71&pages=1181-1185&publication_year=2008&author=Lainakis%2CG&author=Nikos%2CA&author=Gerassimos%2CA's total income per month
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18848786 rake in every month?
- What's the profit of http://scholar.google.com/scholar_lookup?&title=Estramustine%20plus%20docetaxel%20as%20second-line%20therapy%20in%20patients%20with%20hormone-refractory%20prostate%20cancer%20resistant%20to%20docetaxel%20alone&journal=Urol%20Oncol&volume=28&pages=152-156&publication_year=2010&author=Caffo%2CO&author=Sava%2CT&author=Comploj%2CE?
- How much profit does https://doi.org/10.1002%2Fcncr.22811 make?
- What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17577218?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Activity%20of%20second-line%20chemotherapy%20in%20docetaxel-refractory%20hormone-refractory%20prostate%20cancer%20patients%3A%20randomized%20phase%202%20study%20of%20ixabepilone%20or%20mitoxantrone%20and%20prednisone&journal=Cancer&doi=10.1002%2Fcncr.22811&volume=110&pages=556-563&publication_year=2007&author=Rosenberg%2CJE&author=Weinberg%2CVK&author=Kelly%2CWK produce monthly?
- What are the total earnings of https://doi.org/10.1200%2FJCO.2008.19.8002?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19349545 gross monthly?
- What's the income of http://scholar.google.com/scholar_lookup?&title=Phase%20I%20study%20of%20ixabepilone%2C%20mitoxantrone%2C%20and%20prednisone%20in%20patients%20with%20metastatic%20castration-resistant%20prostate%20cancer%20previously%20treated%20with%20docetaxel-based%20therapy%3A%20a%20study%20of%20the%20department%20of%20defense%20prostate%20cancer%20clinical%20trials%20consortium&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2008.19.8002&volume=27&pages=2772-2778&publication_year=2009&author=Rosenberg%2CJE&author=Ryan%2CCJ&author=Weinberg%2CVK?
- How much revenue does https://doi.org/10.1093%2Fannonc%2Fmdn665 produce monthly?
- What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19087985?
- What's http://scholar.google.com/scholar_lookup?&title=Phase%20II%20trial%20of%20weekly%20patupilone%20in%20patients%20with%20castration-resistant%20prostate%20cancer&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdn665&volume=20&pages=492-497&publication_year=2009&author=Hussain%2CA&author=DiPaola%2CRS&author=Baron%2CAD's gross income?
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=A%20multicenter%20phase%20II%20study%20of%20pemetrexed%20as%20second-line%20chemotherapy%20for%20the%20treatment%20of%20hormone%20refractory%20prostate%20cancer%20%28HRPC%29%3B%20Hoosier%20Oncology%20Group%20GU-0367&journal=J%20Clin%20Oncol&volume=26%28S%29&publication_year=2008&author=Hahn%2CNM&author=Zon%2CRT&author=Jones%2CT each month?
- Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Phase%20II%20study%20of%20three%20hour%2C%20weekly%20infusion%20of%20trabectedin%20%28ET-743%29%20in%20men%20with%20metastatic%2C%20androgen-independent%20prostate%20carcinoma%20%28AIPC%29&journal=J%20Clin%20Oncol&volume=23&issue=16%28S%29&publication_year=2005&author=Michaelson%2CMD&author=Gilligan%2CT&author=Oh%2CW
- Profit of https://doi.org/10.1111%2Fj.1464-410X.2008.08327.x
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19154507 generate monthly?
- Revenue of http://scholar.google.com/scholar_lookup?&title=Final%20analysis%20of%20a%20phase%20II%20trial%20using%20sorafenib%20for%20metastatic%20castration-resistant%20prostate%20cancer&journal=BJU%20Int&doi=10.1111%2Fj.1464-410X.2008.08327.x&volume=103&pages=1636-1640&publication_year=2009&author=Aragon-Ching%2CJB&author=Jain%2CL&author=Gulley%2CJL
- How much does https://doi.org/10.1093%2Fannonc%2Fmdp111 gross monthly?
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19403935 generate?
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Phase%20II%20study%20of%20sunitinib%20in%20men%20with%20advanced%20prostate%20cancer&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdp111&volume=20&pages=913-920&publication_year=2009&author=Dror%20Michaelson%2CM&author=Regan%2CMM&author=Oh%2CWK?
- How much does https://doi.org/10.1002%2Fcncr.22439 net monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17186531 generate monthly?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Is%20there%20a%20role%20for%20platinum%20chemotherapy%20in%20the%20treatment%20of%20patients%20with%20hormone-refractory%20prostate%20cancer%3F&journal=Cancer&doi=10.1002%2Fcncr.22439&volume=109&pages=477-486&publication_year=2007&author=Oh%2CWK&author=Tay%2CMH&author=Huang%2CJ produce monthly?
- How much money does https://doi.org/10.1200%2FJCO.2008.20.1228 generate?
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19805692's total income per month
- How much does http://scholar.google.com/scholar_lookup?&title=Multinational%2C%20double-blind%2C%20phase%20III%20study%20of%20prednisone%20and%20either%20satraplatin%20or%20placebo%20in%20patients%20with%20castrate-refractory%20prostate%20cancer%20progressing%20after%20prior%20chemotherapy%3A%20the%20SPARC%20trial&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2008.20.1228&volume=27&pages=5431-5438&publication_year=2009&author=Sternberg%2CCN&author=Petrylak%2CDP&author=Sartor%2CO make?
- How profitable is https://doi.org/10.1093%2Fannonc%2Fmdp308?
- Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19633053
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Efficacy%20of%20carboplatin-taxane%20combinations%20in%20the%20management%20of%20castration-resistant%20prostate%20cancer%3A%20a%20pooled%20analysis%20of%20seven%20prospective%20clinical%20trials&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdp308&volume=21&pages=312-318&publication_year=2009&author=Regan%2CMM&author=O%E2%80%99Donnell%2CEK&author=Kelly%2CWK bring in?
- Monthly income for https://doi.org/10.1111%2Fj.1464-410X.2007.07331.x
- Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18184327 is on a monthly basis
- Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Response%20to%20docetaxel%2Fcarboplatin-based%20chemotherapy%20as%20first-%20and%20second-line%20therapy%20in%20patients%20with%20metastatic%20hormone-refractory%20prostate%20cancer&journal=BJU%20Int&doi=10.1111%2Fj.1464-410X.2007.07331.x&volume=101&pages=308-312&publication_year=2008&author=Nakabayashi%2CM&author=Sartor%2CO&author=Jacobus%2CS
- What is the monthly revenue of https://doi.org/10.1002%2Fcncr.23195?
- What's the financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18085595?
- How much does http://scholar.google.com/scholar_lookup?&title=Prostate%20cancer%20clinical%20trials%20consortium.%20A%20phase%202%20study%20of%20carboplatin%20plus%20docetaxel%20in%20men%20with%20metastatic%20hormone-refractory%20prostate%20cancer%20who%20are%20refractory%20to%20docetaxel&journal=Cancer&doi=10.1002%2Fcncr.23195&volume=112&pages=521-526&publication_year=2008&author=Ross%2CRW&author=Beer%2CTM&author=Jacobus%2CS earn?
- What are the earnings of https://doi.org/10.1093%2Fannonc%2Fmdn694?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19179557 generate?
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Combining%20carboplatin%20and%20etoposide%20in%20docetaxel-pretreated%20patients%20with%20castration-resistant%20prostate%20cancer%3A%20a%20prospective%20study%20evaluating%20also%20neuroendocrine%20features&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdn694&volume=20&pages=703-708&publication_year=2009&author=Loriot%2CY&author=Massard%2CC&author=Gross-Goupil%2CM?
- https://doi.org/10.1159%2F000217264 income
- What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19420966?
- How much does http://scholar.google.com/scholar_lookup?&title=Paclitaxel%2C%20estramustine%20and%20carboplatin%20combination%20chemotherapy%20after%20initial%20docetaxel-based%20chemotherapy%20in%20castration-resistant%20prostate%20cancer&journal=Oncology&doi=10.1159%2F000217264&volume=76&pages=442-446&publication_year=2009&author=Sella%2CA&author=Yarom%2CN&author=Zisman%2CA&author=Kovel%2CS pull in?
- How much does http://scholar.google.com/scholar_lookup?&title=Interim%20results%20of%20a%20phase%20II%20trial%20of%20pemetrexed%20and%20oxaliplatin%20as%202nd%2F3rd%20line%20therapy%20in%20hormone%20refractory%20prostate%20cancer&journal=J%20Clin%20Oncol&volume=26%28S%29&publication_year=2008&author=Dorff%2CTB&author=Groshen%2CSG&author=Wei%2CD net monthly?
- How much does https://doi.org/10.1200%2FJCO.2007.12.4487 generate monthly?
- Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18309951's earnings
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Prostate%20cancer%20clinical%20trials%20working%20group.%20Design%20and%20end%20points%20of%20clinical%20trials%20for%20patients%20with%20progressive%20prostate%20cancer%20and%20castrate%20levels%20of%20testosterone%3A%20recommendations%20of%20the%20Prostate%20Cancer%20Clinical%20Trials%20Working%20Group&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2007.12.4487&volume=26&pages=1148-1159&publication_year=2008&author=Scher%2CHI&author=Halabi%2CS&author=Tannock%2CI?
- https://doi.org/10.1200%2FJCO.2005.15.651's revenue stream
- Financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15994152
- How much does http://scholar.google.com/scholar_lookup?&title=Multicenter%20study%20of%20a%20frozen%20glove%20to%20prevent%20docetaxel-induced%20onycholysis%20and%20cutaneous%20toxicity%20of%20the%20hand&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2005.15.651&volume=23&pages=4424-4429&publication_year=2005&author=Scott%C3%A9%2CF&author=Tourani%2CJM&author=Banu%2CE pull in?
- What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16820898?
- How much does http://scholar.google.com/scholar_lookup?&title=Dose%20and%20outcome%3A%20the%20hurdle%20of%20neutropenia%20%28Review%29&journal=Oncol%20Rep&volume=16&pages=233-248&publication_year=2006&author=Marangolo%2CM&author=Bengala%2CC&author=Conte%2CPF pull in?
- What's the financial gain of https://doi.org/10.1016%2Fj.bone.2008.09.012?
- What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18948230?
- What are the earnings of http://scholar.google.com/scholar_lookup?&title=Osteonecrosis%20of%20the%20jaw%3A%20who%20gets%20it%2C%20and%20why%3F&journal=Bone&doi=10.1016%2Fj.bone.2008.09.012&volume=44&pages=4-10&publication_year=2009&author=Reid%2CIR?
- Learn about the earnings of https://doi.org/10.1097%2F00001813-200211000-00005
- Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12439335
- How much profit is http://scholar.google.com/scholar_lookup?&title=Synergistic%20and%20antagonistic%20combinations%20of%20drugs%20in%20human%20prostate%20cancer%20cell%20lines%20in%20vitro&journal=Anticancer%20Drugs&doi=10.1097%2F00001813-200211000-00005&volume=13&pages=1011-1016&publication_year=2002&author=Budman%2CDR&author=Calabro%2CA&author=Kreis%2CW making per month?
- Learn how profitable https://doi.org/10.1097%2F00001813-200504000-00008 is on a monthly basis
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15746578 pull in monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=In%20vitro%20assessment%20of%20cytotoxic%20agent%20combinations%20for%20hormone-refractory%20prostate%20cancer%20treatment&journal=Anticancer%20Drugs&doi=10.1097%2F00001813-200504000-00008&volume=16&pages=417-422&publication_year=2005&author=Cabrespine%2CA&author=Bay%2CJO&author=Barthomeuf%2CC generate monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17541592 pull in monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=Preclinical%20antitumor%20activity%20of%20the%20oral%20platinum%20analog%20satraplatin&journal=Cancer%20Chemother%20Pharmacol&doi=10.1007%2Fs00280-007-0502-z&volume=60&pages=589-600&publication_year=2007&author=Wosikowski%2CK&author=Lamphere%2CL&author=Unteregger%2CG earn?
- What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12222966 each month?
- How much does http://scholar.google.com/scholar_lookup?&title=Survival%20of%20docetaxel-resistant%20prostate%20cancer%20cells%20in%20vitro%20depends%20on%20phenotype%20alterations%20and%20continuity%20of%20drug%20exposure&journal=Cell%20Mol%20Life%20Sci&doi=10.1007%2Fs00018-002-8498-3&volume=59&pages=1198-1211&publication_year=2002&author=Makarovskiy%2CAN&author=Siryaporn%2CE&author=Hixson%2CDC&author=Akerley%2CW earn?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17024493 generate monthly?
- Income figures for http://scholar.google.com/scholar_lookup?&title=Platinum%28II%29%20complexes%20interfering%20with%20testicular%20steroid%20biosynthesis%3A%20drugs%20for%20the%20therapy%20of%20advanced%20or%20recurrent%20prostate%20cancers%3F%20Preclinical%20studies&journal=J%20Cancer%20Res%20Clin%20Oncol&doi=10.1007%2Fs00432-006-0151-3&volume=133&pages=153-167&publication_year=2007&author=Schertl%2CS&author=Hartmann%2CRW&author=Batzl-Hartmann%2CC
- https://citation-needed.springer.com/v2/references/10.1007/s00345-010-0527-5?format=refman&flavour=references's revenue stream
- Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Christoph%20W.%20M.%20Reuter
- Learn how profitable https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Christoph%20W.%20M.%20Reuter%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en is on a monthly basis
- What's the income generated by https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Michael%20A.%20Morgan each month?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Michael%20A.%20Morgan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's financial summary
- Get to know what's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Philipp%20Ivanyi
- Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Philipp%20Ivanyi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Martin%20Fenner?
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Martin%20Fenner%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en produce monthly?
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Arnold%20Ganser's total income per month
- What's the income generated by https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Arnold%20Ganser%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en each month?
- Profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Viktor%20Gr%C3%BCnwald
- How much cash flow does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Viktor%20Gr%C3%BCnwald%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have monthly?
- What's the financial gain of https://s100.copyright.com/AppDispatchServlet?title=Carboplatin%20plus%20weekly%20docetaxel%20as%20salvage%20chemotherapy%20in%20docetaxel-resistant%20and%20castration-resistant%20prostate%20cancer&author=Christoph%20W.%20M.%20Reuter%20et%20al&contentID=10.1007%2Fs00345-010-0527-5©right=Springer-Verlag&publication=0724-4983&publicationDate=2010-03-14&publisherName=SpringerNature&orderBeanReset=true?
- Income figures for https://citation-needed.springer.com/v2/references/10.1007/s00345-010-0527-5?format=refman&flavour=citation
- What's the financial outcome of https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral?
- What's https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research's gross income?
- What's the financial intake of https://www.springernature.com/gp/products?
- Income figures for https://www.springernature.com/gp/librarians
- Get to know https://www.springernature.com/gp/societies's earnings
- How much profit is https://www.springernature.com/gp/partners making per month?
- https://www.springer.com/'s financial summary
- How much money does https://www.nature.com/ generate?
- Find out how much https://www.biomedcentral.com/ earns monthly
- How much does https://www.palgrave.com/ make?
- What's the profit of https://www.apress.com/?
- See how much https://www.springernature.com/gp/legal/ccpa makes per month
- Explore the financials of https://www.springernature.com/gp/info/accessibility
- How much does https://support.springernature.com/en/support/home pull in?
- How much revenue does https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations produce monthly?
- How much income is https://www.springernature.com/ earning monthly?
Analytics and Tracking {đ}
- Google Tag Manager
Libraries {đ}
- Clipboard.js
- Prism.js
CDN Services {đŠ}
- Crossref